Business
Skye Bioscience Announces Participation at Upcoming Investor Conferences
San Diego, California--(Newsfile Corp. - September 22, 2023) - Skye Bioscience, Inc. (OTCQB: SKYED) ("Skye" or the "Company"), a pharmaceutical company
About this update from Skye Bioscience, Inc.
[{"type":"text","content":"San Diego, California--(Newsfile Corp. - September 22, 2023) - Skye Bioscience, Inc. (OTCQB: SKYED) (\"Skye\" or the \"Company\"), a pharmaceutical company developing proprietary medicines that modulate the endocannabinoid system to treat diseases with inflammatory, fibrotic, and metabolic processes, with a current focus on the CB1 pathway, announced today that it will be presenting a corporate overview at the 2023 Cantor Global Healthcare Conference and the 16th Annual LD Micro Main Event.\n2023 Cantor Global Healthcare Conference\nPresenter: Punit Dhillon, Chairman and CEO\nPresentation date: Wednesday, September 27, 2023\nPresentation time: 11:30 AM ET\nLocation: Intercontinental Barclay New York Hotel, New York\nMr. Dhillon will be available for 1:1 meetings onsite with registered investors during the conference.\n16th Annual LD Micro Main Event\nPresenter: Tu Diep, Chief Development Officer\nPresentation date: Tuesday, October 3\nPresentation time: 4:00 PM PT\nLocation: Luxe Sunset Boulevard Hotel, California\n\nWe invite interested parties to register to watch the presentation virtually here: https://me23.sequireevents.com.\nMr. Diep and Kaitlyn Arsenault, Skye's Chief Financial Officer, will be available for 1:1 meetings onsite throughout the conference.\nAbout Skye Bioscience\nSkye is focused on unlocking the pharmaceutical potential of the endocannabinoid system, initially through modulation of the CB1 receptor. Backed by leading biotechnology venture investors, Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first- and only-in-class therapeutics with significant clinical and commercial differentiation. Nimacimab, a negative allosteric modulating antibody, inhibits peripheral CB1 with unprecedented safety and tolerability. Skye plans to start a Phase 2 basket study of nimacimab for chronic kidney disease in Q1 2024 and is also evaluating potential development paths for related to obesity/weight loss. SBI-100 Ophthalmic Emulsion is a CB1 agonist that is a potential treatment for glaucoma; it will start Phase 2 in Q4 2023, with an interim data readout in Q1 2024. For more information, please visit: https://www.skyebioscience.com.\nCONTACT\nInvestor Relations\nEmail: [email protected] Phone: (858) 410-0266\nFORWARD-LOOKING STATEMENTS\nThis press release contai...